Literature DB >> 28503558

Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?

Eugene J Koay1, Bruno C Odisio2, Milind Javle3, Jean-Nicolas Vauthey4, Christopher H Crane5.   

Abstract

Intrahepatic cholangiocarcinoma often causes death due to obstruction of the biliary system or interruption of the vascular supply of the liver. This fact emphasizes the critical need for local tumor control in this disease. Successful local tumor control has traditionally been achievable through surgical resection for the small proportion of patients with operable tumors. Technological advances in radiation oncology and in interventional radiology have enabled the delivery of ablative radiation doses or other cytotoxic therapies for tumors in the liver. In some cases, this has translated into substantial prolongation of life for patients with this disease, but the indications for these different treatment options are still the subject of ongoing debate. Here, we review the technological advances and clinical studies that are changing the way intrahepatic cholangiocarcinoma is managed, and discuss ways to achieve individualized treatment of patients.

Entities:  

Keywords:  Radiation; Y90; cholangiocarcinoma; personalized medicine

Year:  2017        PMID: 28503558      PMCID: PMC5411273          DOI: 10.21037/hbsn.2017.01.16

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  61 in total

Review 1.  Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis.

Authors:  Kichang Han; Heung Kyu Ko; Kyung Won Kim; Hyung Jin Won; Yong Moon Shin; Pyo Nyun Kim
Journal:  J Vasc Interv Radiol       Date:  2015-04-18       Impact factor: 3.464

2.  MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation.

Authors:  Y Maetani; K Itoh; C Watanabe; T Shibata; F Ametani; H Yamabe; J Konishi
Journal:  AJR Am J Roentgenol       Date:  2001-06       Impact factor: 3.959

3.  Clinicopathologic studies on perineural invasion of bile duct carcinoma.

Authors:  M R Bhuiya; Y Nimura; J Kamiya; S Kondo; S Fukata; N Hayakawa; S Shionoya
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

4.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

5.  Radiofrequency ablation for incidentally identified primary intrahepatic cholangiocarcinoma.

Authors:  Witold Zgodzinski; N-Joseph Espat
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

6.  Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models.

Authors:  Justin K Mikell; Armeen Mahvash; Wendy Siman; Veera Baladandayuthapani; Firas Mourtada; S Cheenu Kappadath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-27       Impact factor: 7.038

7.  Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.

Authors:  Juan C Camacho; Nima Kokabi; Minzhi Xing; Hasmukh J Prajapati; Bassel El-Rayes; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2014-02       Impact factor: 3.464

8.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

9.  Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma.

Authors:  S Herber; G Otto; J Schneider; N Manzl; I Kummer; S Kanzler; A Schuchmann; J Thies; C Düber; M Pitton
Journal:  Cardiovasc Intervent Radiol       Date:  2007-05-17       Impact factor: 2.740

10.  OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma.

Authors:  Guido Poggi; A Amatu; B Montagna; P Quaretti; C Minoia; C Sottani; L Villani; B Tagliaferri; F Sottotetti; O Rossi; E Pozzi; F Zappoli; A Riccardi; G Bernardo
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11       Impact factor: 2.740

View more
  9 in total

Review 1.  Radiation dose escalation for locally advanced unresectable intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Santiago Avila; Danyal A Smani; Eugene J Koay
Journal:  Chin Clin Oncol       Date:  2019-12-19

Review 2.  Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings.

Authors:  Mohammed Saleh; Mayur Virarkar; Vlad Bura; Raul Valenzuela; Sanaz Javadi; Janio Szklaruk; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11

3.  Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation.

Authors:  Jessica M Molkentine; Tara N Fujimoto; Thomas D Horvath; Aaron J Grossberg; Carolina J Garcia Garcia; Amit Deorukhkar; Marimar de la Cruz Bonilla; Daniel Lin; Errol L G Samuel; Wai Kin Chan; Philip L Lorenzi; Helen Piwnica-Worms; Robert Dantzer; James M Tour; Kathryn A Mason; Cullen M Taniguchi
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

4.  Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma.

Authors:  Nikhil T Sebastian; Yubo Tan; Eric D Miller; Terence M Williams; Dayssy Alexandra Diaz
Journal:  Clin Transl Radiat Oncol       Date:  2019-07-26

5.  Preoperative risk grade predicts the long-term prognosis of intrahepatic cholangiocarcinoma: a retrospective cohort analysis.

Authors:  Jianping Zhao; Yao Chen; Jingjing Wang; Jian Wang; Ying Wang; Songshan Chai; Yuxin Zhang; Xiaoping Chen; Wanguang Zhang
Journal:  BMC Surg       Date:  2021-03-06       Impact factor: 2.102

6.  Progress toward improving outcomes in patients with cholangiocarcinoma.

Authors:  Hiroko Kawasaki; Yuko Akazawa; Nataliya Razumilava
Journal:  Curr Treat Options Gastroenterol       Date:  2021-01-30

7.  Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma.

Authors:  Shaohua Li; Min Deng; Qiaoxuan Wang; Jie Mei; Jingwen Zou; Wenping Lin; Ming Shi; Minshan Chen; Wei Wei; Rongping Guo
Journal:  J Oncol       Date:  2022-03-15       Impact factor: 4.375

8.  Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis.

Authors:  Andrew R Kolarich; Jehan L Shah; Thomas J George; Steven J Hughes; Christiana M Shaw; Brian S Geller; Joseph R Grajo
Journal:  J Gastrointest Oncol       Date:  2018-06

9.  Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma.

Authors:  Brian De; Ibrahim Abu-Gheida; Aashini Patel; Sylvia S W Ng; Mohamed Zaid; Connor P Thunshelle; Dalia Elganainy; Kelsey L Corrigan; Michael K Rooney; Milind Javle; Kanwal Raghav; Sunyoung S Lee; Jean-Nicolas Vauthey; Ching-Wei D Tzeng; Hop S Tran Cao; Ethan B Ludmir; Bruce D Minsky; Grace L Smith; Emma B Holliday; Cullen M Taniguchi; Albert C Koong; Prajnan Das; Eugene J Koay
Journal:  J Pers Med       Date:  2021-12-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.